Literature DB >> 7546881

[Late complications of chemoradiotherapeutic combinations: fundamental aspects and clinical experience].

J Balosso1, J F Minne, E Touboul.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7546881

Source DB:  PubMed          Journal:  Bull Cancer Radiother        ISSN： 0924-4212


× No keyword cloud information.
  3 in total

1.  The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution.

Authors:  Frédérique Mégnin-Chanet; François Lavelle; Vincent Favaudon
Journal:  BMC Pharmacol       Date:  2002-02-06

2.  Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells.

Authors:  Y Tao; P Zhang; V Frascogna; Y Lecluse; A Auperin; J Bourhis; E Deutsch
Journal:  Br J Cancer       Date:  2007-11-20       Impact factor: 7.640

3.  Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro.

Authors:  N Giocanti; C Hennequin; D Rouillard; R Defrance; V Favaudon
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.